Akashi Therapeutics Receives Fast Track Designation for HT-100 from FDA for the Treatment of Duchenne Muscular Dystrophy

Akashi Therapeutics, Inc., announced on July 3 that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s most advanced product candidate, HT-100 (delayed-release halofuginone), an orally available, small molecule drug candidate intended to reduce fibrosis and inflammation and promote healthy muscle regeneration in boys with DMD. Fast track designation is granted by the FDA to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.

“We are pleased that the FDA supports our application for fast track designation for HT-100 for the treatment of DMD. This, along with the previously granted orphan drug designation for HT-100, is an important regulatory milestone for the program,” said Marc B. Blaustein, CEO of Akashi Therapeutics. “We will continue to work closely with the FDA as we advance HT-100 through clinical development and the associated regulatory processes.”

Akashi is currently treating patients with DMD in a phase 1b/2a multi-center clinical program to evaluate HT-100 safety and tolerability and assess trends in a range of exploratory biomarkers and efficacy endpoints.

Click here for the full press release.
Halos Ride for Life, August 9, Milton, West Virginia

Climb to Cure Duchenne, August 22-24, Mt. Adams, Washington


2nd Annual All In for Duchenne, October 4, Sylvania, Ohio
Akashi Therapeutics Receives Fast Track Designation for HT-100 from FDA for the Treatment of Duchenne Muscular Dystrophy

Akashi Therapeutics, Inc., announced on July 3 that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s most advanced product candidate, HT-100 (delayed-release halofuginone), an orally available, small molecule drug candidate intended to reduce fibrosis and inflammation and promote healthy muscle regeneration in boys with DMD. Fast track designation is granted by the FDA to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.

“We are pleased that the FDA supports our application for fast track designation for HT-100 for the treatment of DMD. This, along with the previously granted orphan drug designation for HT-100, is an important regulatory milestone for the program,” said Marc B. Blaustein, CEO of Akashi Therapeutics. “We will continue to work closely with the FDA as we advance HT-100 through clinical development and the associated regulatory processes.”

Akashi is currently treating patients with DMD in a phase 1b/2a multi-center clinical program to evaluate HT-100 safety and tolerability and assess trends in a range of exploratory biomarkers and efficacy endpoints.

Click here for the full press release.
Halos Ride for Life, August 9, Milton, West Virginia

Climb to Cure Duchenne, August 22-24, Mt. Adams, Washington


2nd Annual All In for Duchenne, October 4, Sylvania, Ohio
Summit Presents New Data from Phase 1b Clinical Trial of SMT C1100 for Treatment of DMD

Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy ('DMD') and C. difficile infection, reports new data from its recently completed Phase 1b clinical trial of the utrophin modulator SMT C1100 for the treatment of DMD. The data was reported at the 13th International Congress on Neuromuscular Diseases ('ICNMD') that was held between July 5-10 in Nice, France. The results of this study showed a statistically significant decrease in key enzymes associated with muscle damage and support the proposed mechanism of action of SMT C1100.

"These new data from the Phase 1b clinical trial of SMT C1100 provide further encouragement regarding the potential of our utrophin modulator as a disease modifying treatment for all patients with DMD," commented Glyn Edwards, Chief Executive Officer of Summit. "The reduction during drug dosing in enzyme markers normally associated with muscle damage provides an intriguing indication of SMT C1100 activity in these patients. We look forward to progressing SMT C1100 into future trials."

The new data reports the impact of dosing with SMT C1100 on blood levels of the enzymes creatine kinase ('CK'), aspartate aminotransferase ('AST') and alanine aminotransferase ('ALT'). The levels of these enzymes are normally very low in healthy people but in patients with DMD, muscle cells are weakened by the lack of dystrophin causing these enzymes to leak out and accumulate in the blood. During dosing with SMT C1100, a statistically significant reduction in CK, AST and ALT levels was observed when compared to pre-dose baseline levels. Blood levels of these enzymes increased towards pre-dosing levels after dosing stopped.

These data are consistent with the proposed mechanism of action of the utrophin modulator SMT C1100, whereby its effect would result in lower muscle damage and lead to lower levels of these key markers in the blood. The data from this Phase 1 study are encouraging and clearly support further evaluation in a placebo-controlled study.

Click here for the full press release.
Halos Ride for Life, August 9, Milton, West Virginia

Climb to Cure Duchenne, August 22-24, Mt. Adams, Washington


2nd Annual All In for Duchenne, October 4, Sylvania, Ohio
PTC Therapeutics Announces Expanded Access Program For Translarna™ (ataluren)

PTC Therapeutics, Inc. (NASDAQ: PTCT) on July 9 announced the initiation of a reimbursed expanded access program (EAP). PTC's EAP program is intended to make Translarna™ (ataluren) available to patients before commercial availability in certain countries. Where mechanisms exist and in accordance with local regulations, PTC will make Translarna available to nonsense mutation Duchenne muscular dystrophy (nmDMD) patients through funded EAP programs.

Funded Named Patient Programs have already been authorized in Turkey and Spain. Today, the French National Agency for Medicines and Health Products Safety (ANSM), has granted a Temporary Authorization for Use (Autorisation Temporaire d'Utilisation de cohorte). Government allocations to hospitals will allow payment for Translarna for patients included in the ATU cohort program.

"For children and young men living with DMD, a rapidly progressing muscle wasting disorder, every day counts. We are committed to working with regulators, payors and the DMD community to enable Translarna to reach patients as soon as possible wherever reimbursed EAP mechanisms exist," stated Mark Rothera, Chief Commercial Officer of PTC Therapeutics, Inc.

Click here for the full press release.
Halos Ride for Life, August 9, Milton, West Virginia

Climb to Cure Duchenne, August 22-24, Mt. Adams, Washington


2nd Annual All In for Duchenne, October 4, Sylvania, Ohio
Sarepta Therapeutics Reports Long-Term Outcomes Through 144 Weeks from Phase IIb Study of Eteplirsen in Duchenne Muscular Dystrophy

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-based therapeutics, on July 10 announced data through Week 144 from Study 202, a Phase IIb open-label extension study of eteplirsen in patients with Duchenne muscular dystrophy (DMD). After nearly three years of follow up, results on the 6-minute walk test (6MWT) showed a decline in walking ability at a rate slower than would be expected based on available DMD natural history data. In addition, a continued stabilization of respiratory muscle function was observed, as assessed by pulmonary function tests. As previously reported, Study 202 met its primary endpoint of increased novel dystrophin as assessed by muscle biopsy at Week 48 and is now in the long-term extension phase in which patients continue to be followed for safety and clinical outcomes.

At Week 144, patients in the 30 mg/kg and 50 mg/kg eteplirsen cohorts who were able to perform the 6MWT (modified Intent-to-Treat or mITT population; n=6) experienced a decline of 33.2 meters, or about 8.5 percent, from baseline in walking ability. A statistically significant treatment benefit of 75.1 meters ($p \leq 0.004$) was observed for the mITT population compared with the placebo/delayed-treatment cohort (n=4), which initiated treatment at Week 25 following 24 weeks of placebo. After experiencing a substantial decline of 68.4 meters from baseline to Week 36, the placebo/delayed-treatment cohort demonstrated a decline of 39.0 meters in walking ability from Week 36 through Week 144, the period from which meaningful levels of dystrophin were likely produced. These analyses were based on the maximum 6MWT score when the test was performed on two consecutive days.

“The long-term clinical data for eteplirsen showing a slowing in the decline of walking ability in a population now on average 12 years old are very encouraging, particularly when compared with the growing body of DMD natural history data which clearly show that similarly aged patients typically experience an increasingly rapid decline in walking ability and lose ambulation in their early teen years,” said Jerry Mendell, M.D., director of the Centers for Gene Therapy and Muscular Dystrophy at Nationwide Children’s Hospital and principal investigator of the Phase IIb study.

“We now have nearly three years of treatment experience with eteplirsen from our Phase IIb clinical study program and, based on guidance from the U.S. Food and Drug Administration earlier this year, we plan to submit these results along with additional data and analysis as part of a New Drug Application for eteplirsen by year-end,” said Chris Garabedian, president and chief executive officer of Sarepta Therapeutics.
Respiratory muscle function from baseline through Week 144 in the Intent-to-Treat population (n=12), as measured by maximum inspiratory and expiratory pressure (MIP and MEP), showed a 14.7 percent mean increase in MIP and a 12.8 percent mean increase in MEP. Analyses of MIP percent predicted (MIP adjusted for weight) and MEP percent predicted (MEP adjusted for age) demonstrated a mean change from 91.7 percent at baseline to 93.9 percent at Week 144 in MIP percent predicted, and a mean change from 79.3 percent at baseline to 75.7 percent at Week 144 in MEP percent predicted. In addition, there was a mean increase in forced vital capacity (FVC), a measure of lung volume, of 11.0 percent. FVC percent predicted (FVC adjusted for age and height) was maintained above a mean of 90 percent at Week 144, with 101.3 percent at baseline and 90.9 percent at Week 144.

“We are encouraged to see continued stability on measures of respiratory muscle function in patients treated with eteplirsen for nearly three years, particularly as declines in MIP and MEP are often the first signs of pulmonary dysfunction in DMD,” said Edward Kaye, M.D., senior vice president and chief medical officer of Sarepta Therapeutics. “As we prepare to submit a New Drug Application for eteplirsen including these data, we are also on track to initiate in the coming months several new clinical studies of eteplirsen in a broader patient population to further characterize the drug’s safety and efficacy profile.”

Through 144 weeks, eteplirsen was well tolerated and there were no reported clinically significant treatment-related adverse events and no treatment-related serious adverse events. In addition, there were no treatment-related hospitalizations or discontinuations.

Click [here](#) for the full press release.
79 Days of Duchenne

79 Videos Raising Awareness to Find a Cure for Duchenne Muscular Dystrophy

CureDuchenne is pleased to launch the 79 Days of Duchenne project with Sarah Burgess, singer-songwriter and contestant on the sixth season of American Idol. More than 79 talented individuals created 79 unique videos to the song “Run Away” written by Burgess to help raise awareness to find a cure for Duchenne muscular dystrophy. Starting July 9, one video will be released every day for the next 79 days.

Every video captures the creativity of the performer, from More Like Me, a Tennessee rock group comprised of triplets who also had help from Robert Mason (Warrant) and Mark Slaughter (Slaughter), to a group of harmonizing sisters, sign language, dancers and puppets but each has the same universal message to help find a cure for Duchenne. The 79 Days of Duchenne videos include all music genres from pop, acoustic, rap, rock, R&B, country, Christian and opera. The project has inspired performers from across from the U.S. as well as internationally from Canada, Indonesia, Jamaica, Morocco, Philippines, Russia, Slovakia, Switzerland and the United Kingdom.

Burgess wrote the song “Run Away” to benefit CureDuchenne, a national nonprofit organization that raises awareness and funds research to find a cure for Duchenne. The Run Away Project was inspired by Burgess’ 7-year-old brother Jacob who lives with Duchenne a progressive muscle-wasting disease that impacts 1 in 3,500 boys. Boys with Duchenne are usually diagnosed by the age of 5, are in a wheelchair by 12 and most don’t survive their mid-20s.

“Duchenne robs my brother and 300,000 boys worldwide of the ability to walk and run,” said Burgess. “Since I cannot give Jacob my healthy muscles, I will dedicate my life to saving his and all who live with Duchenne. We have 79 talented and caring individuals who have decided to be a voice for those affected by Duchenne.”

The number 79 has significance for the Duchenne community. There are 79 exons in the dystrophin gene. Dystrophin is missing in the body of an individual with Duchenne. Without
dystrophin, muscle cells easily become damaged, cannot repair themselves and die, resulting in heart and breathing failure.

The 79 Days of Duchenne videos will be released each day on YouTube and can be found on the 79 Days of Duchenne website (www.smarturl.it/79Days). The first video features Addison Station, a Connecticut band influenced by Train, Bruno Mars, and Maroon 5.

“We are grateful for everyone who has participated in the 79 Days of Duchenne,” said Debra Miller, CEO and founder of CureDuchenne. “These creative videos will help us raise awareness, fund promising research and help accelerate clinical trials to find a cure for this devastating disease so we can save this generation of Duchenne boys.”

All the royalties for “Run Away” will benefit CureDuchenne. “Run Away” can be downloaded through iTunes and other popular digital music retailers (www.smarturl.it/BuyRunAway).

For more information on CureDuchenne go to www.cureduchenne.org or call 949-872-2552. To donate to CureDuchenne go to www.cureduchenne.org/RunAway. Follow us on Facebook, Twitter and YouTube.

If you are interested in participating in the 79 Days of Duchenne project and creating a video, please contact Burgess. She can be reached on Facebook and Twitter, or through her website (www.sarahburgessmusic.com).

Check out the 79 Days of Duchenne newsletters

- Newsletter one
- Newsletter two

To read more about the inspiration of 79 Days of Duchenne, click here.
Climb Mt. Adams with Tyler Armstrong August 22-24

Tyler Armstrong, 10, will be climbing Mt. Adams as a training climb in preparation for reaching the Seven Summits. Tyler has already climbed two of the Seven Summits Mt. Kilimanjaro and Mt. Aconcagua to benefit CureDuchenne, a nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy. Tyler is the youngest person to reach the summit of Mt. Aconcagua.

Tyler is an avid mountain climber who realized he could use his athletic ability to help others. Tyler invites you to Climb to CureDuchenne. Join Tyler and the CureDuchenne team and climb Mt. Adams. Mt. Adams (12,281 ft.) is the second highest mountain in the state of Washington. The climb will be go from Friday, August 22 through Sunday, August 24. Click here for more information about the Mt. Adams climb. To register, click here.

“Some boys my age with Duchenne can’t walk. I want the world to know about Duchenne so they can find a cure. I want Duchenne boys to have a chance to live,” said Tyler.
Pick Your Own Peak

If you are unable to make the Mt. Adams climb, we hope you’ll set your own personal climbing challenge big or small to help us conquer Duchenne. Do it yourself or put together a team and encourage your friends, family and colleagues to support your climb. Create a team or join a team.

**What:** Teams of people across the country will climb a mountain, hill or tall building to raise awareness and fund research to find a cure for Duchenne. This is the sixth annual Climb to CureDuchenne. All funds will benefit CureDuchenne.

**Where:** Any mountain, hill or tall building. No geographic limitations. Anyone, regardless of athletic ability, is encouraged to participate individually or to form a team and secure personal sponsors/contributors for completing the climb.

**When:** We are trying to have as many teams as possible make their climb on August 22-24, the same weekend of the Mt. Adams climb. If those dates do not work, feel free to choose another day that works better.

For more information, contact Karen Harley at karen@cureduchenne.org or 949-872-2552.
Ryan Getzlaf, captain of the Anaheim Ducks, is hosting the fourth annual Getzlaf Golf Shootout to benefit CureDuchenne. This two-day charity golf event includes a reception at Sutra Lounge in Costa Mesa on September 6 and a golf tournament held at the Monarch Beach Golf Links in Dana Point on September 7. The Getzlaf Golf Shootout is an opportunity to interact with your favorite players, play golf and support a great cause. Each foursome will be teamed up with a professional athlete or celebrity for a unique and exciting day on the green.

CureDuchenne is a Newport Beach-based nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy. Duchenne is a progressive muscle-wasting disease that impacts one in every 3,500 boys. Boys are usually diagnosed at age 5, are in a wheelchair by 12 and most don’t survive their mid-20s. Currently there is no cure for Duchenne.

“My wife, Paige, and I are proud to support CureDuchenne and their efforts to find a cure for this devastating disease,” said Getzlaf. “Duchenne boys are on a race against time and they need our help. The disease makes their muscles weaker and weaker and shortens their life. I invite you to join me at the Getzlaf Golf Shootout for a fun event with my fellow hockey players. Let’s help CureDuchenne fund the most promising research and give this generation of Duchenne boys a chance.”

The Getzlaf Golf Shootout brings together athletes, celebrities and community leaders teaming up in support of CureDuchenne. On September 7, the golf course will include a variety of fun activities including a hockey stick putting contest, longest drive contest and dunk tank as well as plenty of food and drink. Watch a video of last year’s event.
Foursomes cost $2,800 and include an athlete or celebrity as a fifth golfer plus eight tickets to the pre-golf dinner reception. Meet and mingle with hockey players at the reception on September 6 at Sutra. There will be a live and silent auction. Individual tickets to the reception are $100. Click here to register now. For sponsorship information, please contact Drew Hoyer, 949-872-2552 or drew@cureduchenne.org.

CureDuchenne has funded seven research projects that have gone into human clinical trials. All the funds raised will support the most promising research to find a cure for Duchenne.
3 For 99: Charity Raises Medical Research Funding for Three Children’s Diseases

After watching a young family friend, Chelsea Lane, lose her battle against Friedreich’s Ataxia, Joe DeBilio knew he had to continue fighting the disease. Two other disorders were affecting young people in Joe’s life. Nathan Mermilliod is suffering with Hemophilia, and Hawken Miller is afflicted with Duchenne muscular dystrophy.

- **Friedreich’s Ataxia** (FA) is a debilitating, life-shortening, degenerative neuro-muscular disorder.
- **Hemophilia** is an inherited blood clotting disorder, occurring primarily in young males, in which one or more of the 15 vital clotting proteins, called clotting factors, are either deficient or inactive.
- **Duchenne Muscular Dystrophy** is a devastating muscular disease in children. Historically, most boys who have Duchenne do not survive beyond their mid-20s. Those that do will be wheelchair bound by age 12.

Joe wanted to help find a cure for these life-shortening children’s diseases. His vision evolved into the creation of a charity that evenly divides an affordable $99 (or more) donation between these three charities, making it easy to donate with just ONE CLICK. With the help of friends Cosmo Taormina, David Kantar, and a generous initial contribution by Al Barilla, the dream has finally come to fruition.

**3 for 99** is a qualified 501(c)(3) organization, with a mission to raise donations for the critical medical research needs of our three deadly children’s diseases: Friedreich’s Ataxia, Hemophilia and Duchenne Muscular Dystrophy.

The charity is affiliated with DONATE FOR GOOD to make giving easy. Please visit the website for more information at www.3for99charity.org.

Thank you Joe for choosing CureDuchenne as one of the three children's medical research charities you support through 3 for 99. We appreciate all your efforts to help us find a cure for our children.
Halos Ride for Life, August 9, Milton, West Virginia

Climb to CureDuchenne, August 22-24, Mt. Adams, Washington


2nd Annual All In for Duchenne, October 4, Sylvania, Ohio
Help Accelerate Research by Donating Blood

Duchenne families:

If you have Duchenne muscular dystrophy and are between the ages 18-25 years old, or if you have a son with Duchenne that age, you can help accelerate research by donating blood.

A research group has requested Sanguine to collect blood from donors diagnosed with Duchenne muscular dystrophy. You can donate blood without leaving home. You will be reimbursed $50 for your time, plus an additional $25 can be donated to CureDuchenne.

For more information about how it works and the study requirements, click here. Click here to sign up.
Halos Ride for Life, August 9, Milton, West Virginia

Climb to Cure Duchenne, August 22-24, Mt. Adams, Washington


2nd Annual All In for Duchenne, October 4, Sylvania, Ohio
FasterCures features a Q&A with Debra Miller, founder and CEO of CureDuchenne, in the **Innovator Spotlight**. FasterCures, a center of the Milken Institute, is an action tank driven by a singular goal to save lives by speeding up and improving the medical research system.

The Q&A highlights CureDuchenne’s successful venture philanthropy model. It focuses on what prompted the creation of CureDuchenne to CureDuchenne’s research and development strategies and the organizations accomplishments including three projects CureDuchenne funded Prosensa Holdings, Sarepta Therapeutics and PTC Therapeutics that are the closest to being the first drugs to be approved for the treatment of Duchenne.

Click [here](#) to review the article.
Halos Ride for Life, August 9, Milton, West Virginia

Climb to Cure Duchenne, August 22-24, Mt. Adams, Washington


2nd Annual All In for Duchenne, October 4, Sylvania, Ohio
New Physical Therapy Video

CureDuchenne and the Duchenne Therapy Network presents physical therapy tips for those with Duchenne muscular dystrophy. This video addresses management of ankle contractures with stretching, AFO night splints, serial casting and orthopedic surgery.

Video Blog 2 - Ankle Mobility Management - Duchenne Therapy Network
Halos Ride for Life, August 9, Milton, West Virginia

Climb to CureDuchenne, August 22-24, Mt. Adams, Washington


2nd Annual All In for Duchenne, October 4, Sylvania, Ohio
Akashi Therapeutics Receives Fast Track Designation for HT-100 from FDA for the Treatment of Duchenne Muscular Dystrophy

By Akashi Admin | July 3, 2014 | News

Cambridge, Mass.—July 3, 2014—Akashi Therapeutics, Inc., announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s most advanced product candidate, HT-100 (delayed-release halofuginone), an orally available, small molecule drug candidate intended to reduce fibrosis and inflammation and promote healthy muscle regeneration in boys with DMD. Fast track designation is granted by the FDA to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.

“We are pleased that the FDA supports our application for fast track designation for HT-100 for the treatment of DMD. This, along with the previously granted orphan drug designation for HT-100, is an important regulatory milestone for the program,” said Marc B. Blaustein, CEO of Akashi Therapeutics. “We will continue to work closely with the FDA as we advance HT-100 through clinical development and the associated regulatory processes.”

Akashi is currently treating patients with DMD in a phase 1b/2a multi-center clinical program to evaluate HT-100 safety and tolerability and assess trends in a range of exploratory biomarkers and efficacy endpoints.

About HT-100

HT-100 (delayed-release halofuginone) is an orally available, small molecule drug candidate designed to reduce fibrosis and inflammation and promote healthy muscle fiber regeneration in DMD patients. HT-100 has been granted orphan designation for DMD in both the U.S. and EU, and fast track designation in the U.S.

About Duchenne muscular dystrophy (DMD)

Affecting approximately 1 in 3,600 boys worldwide, DMD is the most common of the
Duchenne muscular dystrophies and the most lethal genetic disorder of childhood. It is caused by a genetic mutation that renders boys unable to make functional dystrophin, a protein critical for normal muscle function. Young men with DMD show progressive signs of physical impairment as early as age three, lose the ability to walk in their teens, and die of cardiac or respiratory failure in their late twenties or early thirties.

About Akashi Therapeutics

Akashi Therapeutics is a clinical stage biopharmaceutical company whose mission is to develop treatments for Duchenne muscular dystrophy and other rare pediatric diseases. Akashi was founded by leading patient organizations and biotechnology industry veterans and is managed by a seasoned team of drug development experts to impact a central problem in rare diseases: rapid therapy development. Akashi is developing a pipeline of therapies with the goal of transforming Duchenne from a 100% fatal, aggressive muscle-wasting disease to a chronic, manageable condition. For more information, please visit www.akashirx.com.

Akashi Therapeutics Contact:
Marc B. Blaustein, CFA
investors@akashirx.com
617.431.7234

Media Contact:
Gina Nugent, The Yates Network
gina@theyatesnetwork.com

RECENT POSTS

Akashi Therapeutics Receives FDA Clearance to Resume HT-100 Clinical Development

Akashi Therapeutics Announces Plans to Have Three Compounds for Duchenne Muscular Dystrophy in the Clinic in 2017

Akashi Therapeutics Appoints Alka Batycky to Executive Vice-President, Portfolio Management and Operations

Dosing and Enrollment in HT-100 Trial Suspended

Akashi Therapeutics Establishes International Partnership with Grünenthal Group on HT-100 for DMD
Halos Ride for Life, August 9, Milton, West Virginia

All motorcycle fans be sure to register for the Halos Ride for Life event on August 9 in Milton, West Virginia. This poker run will benefit CureDuchenne and help fund promising research to find a cure for Duchenne. The event starts at the American Legion Post 139 at 1207 Main St, Milton, West Virginia 255.

Registration starts at 10:00 a.m. on August 9.
Pre-Register price $20 per rider
Registration on Ride Day $25 per rider
Passengers with shirt $18
Passengers without shirt $10

Click here for more details. For more information, email halosformusculardystrophy.md@gmail.com.

If you can’t make the poker ride but you still want to support the event, click here.
Halos Ride for Life, August 9, Milton, West Virginia

Climb to Cure Duchenne, August 22-24, Mt. Adams, Washington


2nd Annual All In for Duchenne, October 4, Sylvania, Ohio
Climb to CureDuchenne, August 22-24, Mt. Adams, Washington

Join Tyler Armstrong and the CureDuchenne team and climb Mt. Adams. Mt. Adams (12,281 ft.) is the second highest mountain in the state of Washington. The climb will be go from Friday, August 22 through Sunday, August 24. Click here for more information about the Mt. Adams climb. To register, click here.

If you are unable to make the Mt. Adams climb, we hope you’ll set your own personal climbing challenge big or small to help us conquer Duchenne. Do it yourself or put together a team and encourage your friends, family and colleagues to support your climb. Create a team or join a team.

For more information, contact Karen Harley at karen@cureduchenne.org or 949-872-2552.
Halos Ride for Life, August 9, Milton, West Virginia

Climb to CureDuchenne, August 22-24, Mt. Adams, Washington


2nd Annual All In for Duchenne, October 4, Sylvania, Ohio
Research
Akashi Therapeutics Receives Fast Track Designation for HT-100 from FDA for the Treatment of Duchenne Muscular Dystrophy
Summit Presents New Data from Phase 1b Clinical Trial of SMT C1100 for Treatment of DMD
PTC Therapeutics Announces Expanded Access Program For Translarna™ (ataluren)
Sarepta Therapeutics Reports Long-Term Outcomes Through 144 Weeks from Phase Ib Study of Eteplirsen in Duchenne Muscular Dystrophy

News
79 Days of Duchenne Climb Mt. Adams with Tyler Armstrong August 22-24
Ryan Getzlaf to Host the 4th Annual Getzlaf Golf Shootout on September 6 and 7
3 For 99: Charity Raises Medical Research Funding for Three Children’s Diseases
Help Accelerate Research by Donating Blood

Recent Success
FasterCures Innovator Spotlight

Duchenne Therapy Network
New Physical Therapy Video

Upcoming Events

Save the date for the 4th Annual Getzlaf Golf Shootout hosted by Ryan Getzlaf, captain of the Anaheim Ducks. This two-day charity golf outing brings together athletes, celebrities and community leaders, all teaming up in support of CureDuchenne.

The event kicks off with our MVP Reception at Sutra Lounge in Costa Mesa on Saturday night, September 6. This private affair features cocktails, gourmet appetizers, silent and live auctions, and complimentary admission to the nightclub when it opens to the public later in the evening.

On Sunday morning, September 7, we’ll head over to the gorgeous Monarch Beach Golf Links in Dana Point for our Golf Tournament, where we’ll team one of our professional athletes with each foursome for a fun and exciting day on the green.

Click here for more information or to buy a foursome. For sponsorship information, please contact Drew Hoyer at drew@cureduchenne.org or 949-872-2552.
Halos Ride for Life, August 9, Milton, West Virginia

Climb to Cure Duchenne, August 22-24, Mt. Adams, Washington


2nd Annual All In for Duchenne, October 4, Sylvania, Ohio
2nd Annual All In for Duchenne, October 4, Sylvania, Ohio

Join us for the 2nd Annual All In for Duchenne presented by Breaden’s Bridge and benefitting CureDuchenne. This fun casino night will be held on Saturday, October 4 at 6:00 p.m. It features dinner, games and a live and silent auction. The fundraiser will be held at Sylvania, Tam-O-Shanter, 7060 W Sylvania Ave in Sylvania, Ohio.

For sponsorship information, contact tammy@BraedansBridgeToEndDuchenne.BlogSpot.com
Halos Ride for Life, August 9, Milton, West Virginia

Climb to Cure Duchenne, August 22-24, Mt. Adams, Washington


2nd Annual All In for Duchenne, October 4, Sylvania, Ohio